Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Sharma MR, Powderly J, Kuboki Y, Strickler JH, Perets R, Cohen JE, Raimbourg J, Nakajima TE, Yamamoto N, Cruz-Correa M, O'Neil B, Ghiringhelli F, Raghav K, Cecchini M, Bar J, Hunter Z, Burns M, Blaney M, Morrison-Thiele G, Aristide MN, Freise KJ, Li R, Li M, Vasilopoulos A, Biesdorf C, Sommerhalder D

Open source

DOI: 10.1200/jco-25-01525
Published: 2026 Jul 10
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-01525,
  title = {Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.},
  author = {Sharma MR and Powderly J and Kuboki Y and Strickler JH and Perets R and Cohen JE and Raimbourg J and Nakajima TE and Yamamoto N and Cruz-Correa M and O'Neil B and Ghiringhelli F and Raghav K and Cecchini M and Bar J and Hunter Z and Burns M and Blaney M and Morrison-Thiele G and Aristide MN and Freise KJ and Li R and Li M and Vasilopoulos A and Biesdorf C and Sommerhalder D},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-25-01525},
  url = {https://doi.org/10.1200/jco-25-01525}
}

RIS

TY  - JOUR
TI  - Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
AU  - Sharma MR
AU  - Powderly J
AU  - Kuboki Y
AU  - Strickler JH
AU  - Perets R
AU  - Cohen JE
AU  - Raimbourg J
AU  - Nakajima TE
AU  - Yamamoto N
AU  - Cruz-Correa M
AU  - O'Neil B
AU  - Ghiringhelli F
AU  - Raghav K
AU  - Cecchini M
AU  - Bar J
AU  - Hunter Z
AU  - Burns M
AU  - Blaney M
AU  - Morrison-Thiele G
AU  - Aristide MN
AU  - Freise KJ
AU  - Li R
AU  - Li M
AU  - Vasilopoulos A
AU  - Biesdorf C
AU  - Sommerhalder D
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-25-01525
UR  - https://doi.org/10.1200/jco-25-01525
ER  -

APA

MR, S., J, P., Y, K., JH, S., R, P., JE, C., J, R., TE, N., N, Y., M, C., B, O., F, G., K, R., M, C., J, B., Z, H., M, B., M, B., G, M., MN, A., KJ, F., R, L., M, L., A, V., C, B., & D, S. (2026). Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-25-01525

Source records

pubmed · retrieved 2026-09-25T11:42:32.669Z
europe-pmc · retrieved 2026-09-25T11:42:32.682Z